Lefmaa 10 Tablet contains Leflunomide 10 mg, an immunomodulatory agent primarily indicated for the treatment of active rheumatoid arthritis and psoriatic arthritis. Leflunomide acts by inhibiting dihydroorotate dehydrogenase, a key enzyme involved in pyrimidine synthesis, thereby reducing the proliferation of activated lymphocytes responsible for inflammatory responses. This mechanism helps to alleviate joint inflammation, pain, and swelling, ultimately improving physical function and slowing disease progression. Lefmaa 10 is typically prescribed as part of a comprehensive treatment plan, which may include other disease-modifying antirheumatic drugs (DMARDs). The tablet should be administered orally, with or without food, as directed by a healthcare professional. Common adverse effects include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain, as well as elevated liver enzymes and potential hepatotoxicity, necessitating regular liver function monitoring during therapy. Patients should be advised regarding the risk of immunosuppression and the importance of reporting signs of infection promptly. Leflunomide is contraindicated in pregnancy due to teratogenicity and requires effective contraception during treatment and washout periods. Overall, Lefmaa 10 Tablet offers a valuable therapeutic option for managing autoimmune inflammatory conditions by modulating immune activity and improving patient quality of life.

Dosage & How to Use